Logo image of EDT.CA

SPECTRAL MEDICAL INC (EDT.CA) Stock Fundamental Analysis

Canada - Toronto Stock Exchange - TSX:EDT - CA8475771033 - Common Stock

1.44 CAD
+0.13 (+9.92%)
Last: 12/31/2025, 7:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to EDT. EDT was compared to 23 industry peers in the Biotechnology industry. EDT has a bad profitability rating. Also its financial health evaluation is rather negative. EDT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EDT has reported negative net income.
EDT had a negative operating cash flow in the past year.
EDT had negative earnings in each of the past 5 years.
EDT had a negative operating cash flow in each of the past 5 years.
EDT.CA Yearly Net Income VS EBIT VS OCF VS FCFEDT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of EDT (-513.23%) is worse than 73.91% of its industry peers.
Industry RankSector Rank
ROA -513.23%
ROE N/A
ROIC N/A
ROA(3y)-227.94%
ROA(5y)-174.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EDT.CA Yearly ROA, ROE, ROICEDT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

With an excellent Gross Margin value of 56.16%, EDT belongs to the best of the industry, outperforming 95.65% of the companies in the same industry.
EDT's Gross Margin has declined in the last couple of years.
EDT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.21%
GM growth 5Y-10.46%
EDT.CA Yearly Profit, Operating, Gross MarginsEDT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

EDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EDT has been increased compared to 1 year ago.
EDT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for EDT is higher compared to a year ago.
EDT.CA Yearly Shares OutstandingEDT.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
EDT.CA Yearly Total Debt VS Total AssetsEDT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

2.2 Solvency

EDT has an Altman-Z score of -39.82. This is a bad value and indicates that EDT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -39.82, EDT is doing worse than 60.87% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -39.82
ROIC/WACCN/A
WACC7.81%
EDT.CA Yearly LT Debt VS Equity VS FCFEDT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

2.3 Liquidity

A Current Ratio of 0.11 indicates that EDT may have some problems paying its short term obligations.
EDT has a worse Current ratio (0.11) than 65.22% of its industry peers.
A Quick Ratio of 0.10 indicates that EDT may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.10, EDT is doing worse than 60.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.1
EDT.CA Yearly Current Assets VS Current LiabilitesEDT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

5

3. Growth

3.1 Past

EDT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -62.68%.
Looking at the last year, EDT shows a very strong growth in Revenue. The Revenue has grown by 34.85%.
The Revenue has been decreasing by -4.45% on average over the past years.
EPS 1Y (TTM)-62.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-197.46%
Revenue 1Y (TTM)34.85%
Revenue growth 3Y3.7%
Revenue growth 5Y-4.45%
Sales Q2Q%37.71%

3.2 Future

Based on estimates for the next years, EDT will show a very strong growth in Earnings Per Share. The EPS will grow by 38.06% on average per year.
The Revenue is expected to grow by 137.88% on average over the next years. This is a very strong growth
EPS Next Y14.29%
EPS Next 2Y25.36%
EPS Next 3Y25.99%
EPS Next 5Y38.06%
Revenue Next Year-14.99%
Revenue Next 2Y43.24%
Revenue Next 3Y82.11%
Revenue Next 5Y137.88%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EDT.CA Yearly Revenue VS EstimatesEDT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
EDT.CA Yearly EPS VS EstimatesEDT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 2032 0 0.2 0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EDT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EDT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EDT.CA Price Earnings VS Forward Price EarningsEDT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EDT.CA Per share dataEDT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15 -0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as EDT's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.36%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

EDT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SPECTRAL MEDICAL INC

TSX:EDT (12/31/2025, 7:00:00 PM)

1.44

+0.13 (+9.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2025-11-07/bmo
Earnings (Next)03-25 2026-03-25/bmo
Inst Owners0.04%
Inst Owner ChangeN/A
Ins Owners1.54%
Ins Owner ChangeN/A
Market Cap416.39M
Revenue(TTM)2.71M
Net Income(TTM)-41.70M
Analysts83.33
Price Target3.16 (119.44%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.81%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-100%
EPS NY rev (3m)-100%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-25.62%
Revenue NY rev (3m)-25.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 153.93
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.01
BVpS-0.24
TBVpS-0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -513.23%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.16%
FCFM N/A
ROA(3y)-227.94%
ROA(5y)-174.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.21%
GM growth 5Y-10.46%
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.54%
Cap/Sales 7.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.1
Altman-Z -39.82
F-Score3
WACC7.81%
ROIC/WACCN/A
Cap/Depr(3y)35.44%
Cap/Depr(5y)73.91%
Cap/Sales(3y)4.85%
Cap/Sales(5y)10.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-197.46%
EPS Next Y14.29%
EPS Next 2Y25.36%
EPS Next 3Y25.99%
EPS Next 5Y38.06%
Revenue 1Y (TTM)34.85%
Revenue growth 3Y3.7%
Revenue growth 5Y-4.45%
Sales Q2Q%37.71%
Revenue Next Year-14.99%
Revenue Next 2Y43.24%
Revenue Next 3Y82.11%
Revenue Next 5Y137.88%
EBIT growth 1Y50.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.79%
OCF growth 3YN/A
OCF growth 5YN/A

SPECTRAL MEDICAL INC / EDT.CA FAQ

What is the ChartMill fundamental rating of SPECTRAL MEDICAL INC (EDT.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to EDT.CA.


What is the valuation status for EDT stock?

ChartMill assigns a valuation rating of 1 / 10 to SPECTRAL MEDICAL INC (EDT.CA). This can be considered as Overvalued.


What is the profitability of EDT stock?

SPECTRAL MEDICAL INC (EDT.CA) has a profitability rating of 1 / 10.